Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator

被引:17
作者
Kaczmarek, Jakub Zbigniew [1 ]
Skottrup, Peter Durand [1 ]
机构
[1] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2650 Hvidovre, Denmark
关键词
Nanobody; Phage display; Serine protease; Single domain antibody; Antibody technology; DOMAIN ANTIBODY FRAGMENTS; SACCHAROMYCES-CEREVISIAE; BOTULINUM NEUROTOXIN; MONOCLONAL-ANTIBODY; BREAST-CANCER; ENZYME; INHIBITORS; RECEPTOR; VHH; UPA;
D O I
10.1016/j.molimm.2015.02.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urokinase-type plasminogen activator (uPA) is a trypsin-like serine protease that plays a vital role in extracellular conversion of inactive plasminogen into catalytically active plasmin. Activated plasmin facilitates the release of several proteolytic enzymes, which control processes like pericellular proteolysis and remodeling of ECM. uPA and the receptor uPAR, are overexpressed in a number of malignant tumouts and uPA/uPAR play major roles in adhesion, migration, invasion and metastasis of cancer cells. Elevated levels of uPA have been reported as a risk biomarker for disease relapse, increased cancer malignancy and poor survival prognosis. For these reasons uPA is considered an important target for anticancer drug therapy. In this study we isolated two camel single domain antibodies (nanobodies) from a naive library by phage display. The nanobody sequences were sequence-optimized for Escherichia coli expression, cloned into the pET22-B(+) vector system, expressed in BL-21 cells and purified from the periplasmic fraction by IMAC. ELISA tests demonstrated that the purified nanobodies were specific for uPA when tested towards other trypsin-like serine proteases. The apparent affinities of the nanobodies were determined by competitive ELISA to 80 nM and 522 nM, respectively. The best binder did not inhibit uPA (nAb-C3), however the lowest affinity binder (nAb-C8) was able to inhibit the uPA-mediated cleavage of the substrate S-2444. The results validate the naive library as a resource for retrieval of relevant lead molecules and the novel uPA-nanobodies can be useful pharmacological tools to study uPA structure-function relationships. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 46 条
[1]   Cell selection and characterization of a novel human endothelial cell specific nanobody [J].
Ahmadvand, Davoud ;
Rasaee, Mohammad J. ;
Rahbarizadeh, Fatemeh ;
Kontermann, Roland E. ;
Sheikholislami, Farzaneh .
MOLECULAR IMMUNOLOGY, 2009, 46 (8-9) :1814-1823
[2]   A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue [J].
Andersen, Lisbeth M. ;
Wind, Troels ;
Hansen, Hanne D. ;
Andreasen, Peter A. .
BIOCHEMICAL JOURNAL, 2008, 412 (447-457) :447-457
[3]   Evolving role of uPA/uPAR system in human cancers [J].
Ass, Kathleen ;
Ahmad, Aamir ;
Azmi, Asfar S. ;
Sarkar, Sarah H. ;
Sarkar, Fazlul H. .
CANCER TREATMENT REVIEWS, 2008, 34 (02) :122-136
[4]  
Carriero MV, 2009, FRONT BIOSCI-LANDMRK, V14, P3782, DOI [10.2741/3488, 10.2735/3488]
[5]   Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils [J].
Chan, Pak-Ho ;
Pardon, Els ;
Menzer, Linda ;
De Genst, Erwin ;
Kumita, Janet R. ;
Christodoulou, John ;
Saerens, Dirk ;
Brans, Alain ;
Bouillenne, Fabrice ;
Archer, David B. ;
Robinson, Carol V. ;
Muyldermans, Serge ;
Matagne, Andre ;
Redfield, Christina ;
Wyns, Lode ;
Dobson, Christopher M. ;
Dumoulin, Mireille .
BIOCHEMISTRY, 2008, 47 (42) :11041-11054
[6]   Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase [J].
Conrath, Katja ;
Pereira, Alice S. ;
Martins, Carlos E. ;
Timoteo, Cristina G. ;
Tavares, Pedro ;
Spinelli, Silvia ;
Kinne, Joerg ;
Flaudrops, Christophe ;
Cambillau, Christian ;
Muyldermans, Serge ;
Moura, Isabel ;
Moura, Jose J. G. ;
Tegoni, Mariella ;
Desmyter, Aline .
PROTEIN SCIENCE, 2009, 18 (03) :619-628
[7]   INHIBITION OF A PLASMINOGEN-ACTIVATOR FROM ONCOGENIC VIRUS-TRANSFORMED MOUSE CELLS BY RABBIT ANTIBODIES AGAINST THE ENZYME [J].
DANO, K ;
NIELSEN, LS ;
MOLLER, V ;
ENGELHART, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 630 (01) :146-151
[8]   Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies [J].
De Genst, E ;
Silence, K ;
Decanniere, K ;
Conrath, K ;
Loris, R ;
Kinne, R ;
Muyldermans, S ;
Wyns, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (12) :4586-4591
[9]   Nanobody-based products as research and diagnostic tools [J].
De Meyer, Thomas ;
Muyldermans, Serge ;
Depicker, Ann .
TRENDS IN BIOTECHNOLOGY, 2014, 32 (05) :263-270
[10]   Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients [J].
de Witte, JH ;
Sweep, CGJ ;
Klijn, JGM ;
Grebenschikov, N ;
Peters, HA ;
Look, MP ;
van Tienoven, TH ;
Heuvel, JJTM ;
van Putten, WLJ ;
Benraad, TJ ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1190-1198